[
  {
    "ts": null,
    "headline": "How to use the tax-loss selling occurring now to pick up quality stocks on the cheap",
    "summary": "Kevin Simpson on how to use this annual phenomenon to your advantage.",
    "url": "https://finnhub.io/api/news?id=e8449d281e805266fdfb6e00a367cb755b8a8d8d4d4688cbe8df21dd35958175",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763462160,
      "headline": "How to use the tax-loss selling occurring now to pick up quality stocks on the cheap",
      "id": 137539478,
      "image": "https://image.cnbcfm.com/api/v1/image/108226832-1763392836480-gettyimages-2247138010-mms16768_m2ynxbly.jpeg?v=1763392911&w=1920&h=1080",
      "related": "JNJ",
      "source": "CNBC",
      "summary": "Kevin Simpson on how to use this annual phenomenon to your advantage.",
      "url": "https://finnhub.io/api/news?id=e8449d281e805266fdfb6e00a367cb755b8a8d8d4d4688cbe8df21dd35958175"
    }
  },
  {
    "ts": null,
    "headline": "Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?",
    "summary": "Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at RXRX stock and its latest earnings.",
    "url": "https://finnhub.io/api/news?id=07ff206a122b4ea7729f18bab5dce1dcb5e21779ca9765eebb0e4c3588fb62de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763460874,
      "headline": "Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?",
      "id": 137538047,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412857430/image_1412857430.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at RXRX stock and its latest earnings.",
      "url": "https://finnhub.io/api/news?id=07ff206a122b4ea7729f18bab5dce1dcb5e21779ca9765eebb0e4c3588fb62de"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to acquire Halda Therapeutics for $3.05bn",
    "summary": "The acquisition brings Halda's candidate HLD-0915, a clinical-stage treatment for prostate cancer, into J&J's oncology portfolio.",
    "url": "https://finnhub.io/api/news?id=b8cf6413c6a24198da9c3a02b0824bc11f00b2c490d6a4148ce024e4a1c7f909",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763460787,
      "headline": "Johnson & Johnson to acquire Halda Therapeutics for $3.05bn",
      "id": 137538233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The acquisition brings Halda's candidate HLD-0915, a clinical-stage treatment for prostate cancer, into J&J's oncology portfolio.",
      "url": "https://finnhub.io/api/news?id=b8cf6413c6a24198da9c3a02b0824bc11f00b2c490d6a4148ce024e4a1c7f909"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum",
    "summary": "Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.",
    "url": "https://finnhub.io/api/news?id=0f44308c847b02b8a6c83cff8c6d58316ba5a840e96deba9937d471caa822371",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763458020,
      "headline": "The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum",
      "id": 137538227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.",
      "url": "https://finnhub.io/api/news?id=0f44308c847b02b8a6c83cff8c6d58316ba5a840e96deba9937d471caa822371"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Expands Oncology Pipeline with $3.05 Billion Halda Acquisition",
    "summary": "Deal adds new prostate cancer candidate and supports J&J's long-term oncology strategy.",
    "url": "https://finnhub.io/api/news?id=c8c3b4d7af00e43f58c2a108feb334ac1aa16b9bf2e68803a6ebde98abc63096",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763446611,
      "headline": "Johnson & Johnson Expands Oncology Pipeline with $3.05 Billion Halda Acquisition",
      "id": 137522812,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Deal adds new prostate cancer candidate and supports J&J's long-term oncology strategy.",
      "url": "https://finnhub.io/api/news?id=c8c3b4d7af00e43f58c2a108feb334ac1aa16b9bf2e68803a6ebde98abc63096"
    }
  }
]